WO1994004186A1 - Compositions homeopathiques pour le traitement des maladies virales et metaboliques - Google Patents

Compositions homeopathiques pour le traitement des maladies virales et metaboliques Download PDF

Info

Publication number
WO1994004186A1
WO1994004186A1 PCT/FR1992/000813 FR9200813W WO9404186A1 WO 1994004186 A1 WO1994004186 A1 WO 1994004186A1 FR 9200813 W FR9200813 W FR 9200813W WO 9404186 A1 WO9404186 A1 WO 9404186A1
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
intracellular
viral
rxch
homeopathic
Prior art date
Application number
PCT/FR1992/000813
Other languages
English (en)
French (fr)
Inventor
Marie-Christine Etienne
Original Assignee
Etienne Marie Christine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9110899A priority Critical patent/FR2680687A1/fr
Application filed by Etienne Marie Christine filed Critical Etienne Marie Christine
Priority to CA002142863A priority patent/CA2142863A1/fr
Priority to AU25105/92A priority patent/AU2510592A/en
Priority to DE69223811T priority patent/DE69223811T2/de
Priority to EP92918959A priority patent/EP0655928B1/fr
Priority to PCT/FR1992/000813 priority patent/WO1994004186A1/fr
Publication of WO1994004186A1 publication Critical patent/WO1994004186A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to a new therapeutic application of homeopathic remedies for the treatment of metabolic diseases and viral diseases with compounds known or not in the prior art and characterized by the general formula RxCH. 5
  • the metabolic diseases concerned by the invention are diseases characterized by intracellular accumulation or by intracellular deficiency in a chemical body of simple or complex formula, variable according to the case and designated here by R.
  • organotherapy is used:
  • the invention relates to a second therapeutic use of homeopathic remedies which are no longer used according to the law of similarity, the principle of similarity, the principle of infinitimality and pathogenesis to make a sick subject disappear with a series of symptoms. serving at an infinitesimal dose of the same substance which could have caused the same series of symptoms in healthy subjects at a weight dose, but which are used, on the one hand, to cause an elimination of chemical bodies outside the cell and out of it. 'organism, and secondly, by causing this elimination to restore the normal functioning of pericellular transport systems disturbed vis-à-vis these chemical bodies.
  • the invention uses a property of homeopathic dilutions known and experienced only in vitro: from the experiments of Lise WURMSER (since repeated by many authors), it has been observed that a product in homeopathic dilution causes elimination outside the body of the product by weight dose from which it had been prepared, the eliminated product being stored inside the cells; the term product here designating any chemical body.
  • Lise WURMSER and her collaborators injected Arsenic to laboratory animals, then injected these guinea pigs with Arsenic in homeopathic dilution.
  • Lise WURMSER has shown that under the influence of homeopathic dilutions of Arsenic, there was an increased elimination in the urine and in the stools of guinea pigs from the injected Arsenic.
  • the invention aims to use the toxic in homeopathic dilution in order to cause its elimination out of cells and out of the body.
  • the invention aims to use the virus or the fragment of virus in dilution homeopathic in order to cause the elimination from the cells and from the organism of this virus or this fragment of virus.
  • the dilutions used are preferably high in order to cause the strongest possible elimination.
  • Another field of the invention is to have found, by original clinical observations, that this elimination of intracellular elements outside the cell and outside the organism can influence the functioning of the pericellular transport systems in a lasting manner.
  • the invention therefore consists in using this property of eliminating intracellular chemical bodies out of the cell and out of the organism under the influence of their homeopathic dilutions to restore normal functioning of the disturbed pericellular transport systems.
  • ion channels are a special case of these systems for transporting chemical bodies.
  • the invention which is based on these new and original theories consists in using the property of elimination of chemical bodies out of the cell and out of the organism under the influence of their homeopathic dilution, to restore normal functioning of the transport systems. pericellular cells disturbed with respect to these chemical bodies.
  • the ion channels and Pericellular transport systems operate according to concentration gradients passing ions and other substances from the most concentrated medium to the least concentrated medium.
  • the administration of the homeopathic dilution of the excess product in the cell also causes a call for water around the eliminated molecules, because the water follows the minerals and other products and leaves the cell.
  • the extracellular medium occasionally becomes less concentrated than the intracellular medium.
  • the pericellular transport systems corresponding to this location which are regulated by virtue of a concentration gradient, that is to say some of the entry doors tilt to bring out of the cell the product which could only come in.
  • the dilutions used according to the invention are preferably high, for example 15 CH to 30 CH, because these high dilutions cause, according to the invention, a more vigorous elimination than low dilutions. Their action continues for several days in a row, so their intake is spaced 1 to 2 times a week.
  • the intracellular medium deficient and poor in molecules of ions or of another product contains only little water, since water has flocked to the extracellular sector rich in mineral ions (or other product).
  • the inside of the cell has become more concentrated than the outside of the cell, and the transport systems which are regulated according to a concentration gradient and pass from the most concentrated medium to the least concentrated medium, are blocked in the direction of the exit.
  • the administration in this case of the product in intracellular deficiency, in homeopathic dilution causes according to the invention:
  • the dosage of the Homeopathic dilution is as follows: the administration of the Homeopathic dilution of the product concerned must be regular and can last a long time, often several years.
  • the frequency of taking and the height of the dilution of the compounds according to the invention is a matter of particular cases and must be determined by the therapist.
  • the general formula of the compounds is RxCH.
  • Tricalcium phosphate (Calcarea Phosphorica)
  • HIV virus Viruses and viral particles of: HIV virus
  • x 15 CH in dose once a week this as an indication and not limiting: R15CH .
  • the compound RxCH acts on pericellular transport systems with respect to the viral particle by inhibiting its penetration into the cell and by allowing the elimination of the viral particle outside the cell.
  • pericellular receptors allow the entry of the virus into the cell and constituting a true pericellular transport system.
  • the restoration of the normal functioning of the pericellular transport systems cures metabolic anomalies secondary to these dysfunctions, where the relationship with deficiencies or excesses intracellular can be obvious and direct or very indirect and not obvious at all.
  • cystic fibrosis which is a direct consequence of an intracellular excess of NAC1, by disturbance of the pericellular transport systems with respect to NAC1.
  • Tetany by intracellular Magnesium deficiency secondary to a disturbance of the pericellular transport systems vis-à-vis the
  • the cells begin to manufacture all kinds of chemicals of abnormal structure or in abnormal quantity, responsible for the most diverse conditions such as Hypertension if it is a hyperproduction Aldosterone, gout if it is a hyperproduction of uric acid, dyslipemia and atherosclerosis if it is cholesterol or triglycerides in abnormally high amount, and this list is not exhaustive.
  • the correction of dysfunctions of the pericellular transport systems by the use of the homeopathic compounds RxCH also corrects the chromosomal anomalies controlling the dysfunctions of the pericellular transport systems and interrupts the genetic transmission of these diseases.
  • the correction of the dysfunction of the pericellular transport systems acts on the anomalies of the genes located on the chromosomes by also normalizing them.
  • the anomalies in the functioning of the pericellular transport systems can have other origins and other causes than hereditary transmission.
  • the object of the invention is to treat cystic fibrosis with a compound of formula RxCH in which R may be indicative and not limiting, NAC1, or any other salt capable of acting on the ionic overload considered and the defective ion channel such as potassium chloride, sodium iodide, iodine chloride, or salts composed of sodium, chlorine, potassium and iodine, comprising all or some of these elements, and where x can preferably be equal to 15 or 30.
  • Example 3 Oxalosis It is a so-called genetic disease in which there is an intracellular accumulation of oxalic acid or calcium oxalate. This condition is observed in children and leads to death from renal failure.
  • the invention consists in treating oxalose with the compound RxCH in which R can preferably be: Oxalic acid or calcium oxalate and where x can preferably be equal to 5, 15 or 30.
  • RxCH may preferably be Aluminum, or 1 other salt or derivative of Aluminum, and x may preferably be equal to 5, 15, or 30.
  • the invention in this case relates to the use of the compound RxCH in which R is dimagnesian phosphate (Magnesia phosphorica) and where x is preferably equal to 4CH, 6DH, 5CH or 7CH to treat the form of so-called genetic Tetanyus.
  • Example 9 Vitamin-resistant rickets It is a particular form of rickets in children.
  • the present invention consists in treating this condition with the compound RxCH where R can preferably be:
  • RxCH where R may preferably be for information Potassium or 1 potassium salt for example dipotassium phosphate or Kalium phosphoricum active product well known in homeopathy and where x may preferably be equal to 5.
  • Example 11 Intra-cellular iron deficiency anemia. It is a little known condition characterized by small red blood cells and low hematocrit, which manifests as symptoms of anemia.
  • the invention consists in treating this form of anemia with the compound RxCH where R is preferably iron and where x is preferably equal to 5.
  • the invention also relates to the treatment of other autoimmune conditions not accompanied by polyarthritis by the same compound RxCH where R is preferably the black sulfide of Antimony.
  • RxCH where R is preferably the black sulfide of Antimony.
  • the invention relates to the treatment of this autoimmune condition with the compound RxCH in which R is preferably OR and where x is preferably equal to 4, 5 or 7.
  • this incurable disease could be an autoimmune disease by an abnormality of the pericellular transport systems with respect to the phosphorus.
  • the object of the invention is therefore to treat this disease with the compound RxCH where R can preferably be Phosphorus, or a salt derived from Phosphorus and where x can preferably be equal to 5, 15 or 30.
  • Multiple sclerosis is a very similar disease, benefiting from the same type of treatment with the same compound RxCH where R may preferably be Phosphorus or a salt derived from phosphorus.
  • the compound RxCH according to the invention has the property of bringing viral particles out of the infected cells and then of causing their elimination in the form of an inactive compound by the natural routes.
  • the inactive compound is due to the combination of the viral particle at a weight dose exited from the cell and its homeopathic dilution. It may also be thought that the homeopathic dilution prepared on the basis of viral particles can act on pericellular transport systems with respect to these viral particles, by preventing the intracellular penetration of these viral particles.
  • the viral particles are held by the Institut Pasteur which uses them for techniques of molecular hybridization of nucleic acid and for techniques of genetic engineering which consists in making viral proteins manufactured by microorganisms to which viral genes have been injected. These viral particles are also used to carry out serologies or for experimental purposes for the development of vaccines.
  • the viral particles are also held by the Pasteur Institute.
  • the viral affections concerned by the invention can be any viral affection and by way of indication and nonlimiting, one will mention AIDS, Hepatitis A, B or C etc., cancer with virus, neurological diseases with slow or fast virus, animal viral diseases such as cat retrovirus feline leukosis, bovine leukosis, dog lentivirus lymphosarcoma.
  • viral particles are normal constituents of certain vaccines or are held by veterinary pharmaceutical or experimental laboratories.
  • Refsum's disease or R can be Phytanic acid, Charcot Marie Tooth's and Dejerine Sottas' disease, Huntington's chorea where R can be zinc, Thevenard's disease, Friedrich's disease, hereditary cerebellar ataxia of Pierre Marie, the familial paralysis of Strumpell Lorrain, the aréflexie dystasia of Roussy Lévis, dyslipidoses, Idiopathic mental retardation of the child, autism.
  • the general condition is better.
  • the tremor is less pronounced.
  • a new dosage of serum iron is requested 2 1/2 months later, at the end of January, i.e. 2 1/2 months after stopping treatment for one month by
  • TSH levels are 0.2 to 4 and T41 10 to 25. TSH is abnormally low and free T4 is abnormally high.
  • the patient receives a synthetic antithyroid treatment, only with Basdene from the
  • Neomercazole is prescribed in doses of 3cp 3 times a day on 17-03 TSH: 0.02 T41: 33.8
  • the level of thyroid hormone after 10 days of neomercazole is still as high, without any improvement.
  • the thyroid hormone level for the first time returned to normal and the abundance of allergic rhinitis decreased by 3/4.
  • the Neomercazole which normalized the thyroid functions, one abruptly stops the Neomercazole, which must have the effect if it is the Neomercazole which lowered the T41, to immediately raise it to 30 and we continue the regular intake of
  • Natrum Muriaticum 6DH 3 tablets / day from 20-03 to 11-04 then Natrum Muriaticum 4CH: 3 granules / day from 11-04 to 28-04.
  • Muriaticum which is increased due to Natrum Muriaticum 5CH: 3 granules per day.
  • Thyroid functions are therefore normal.
  • the allergic rhinitis has disappeared, the Natrum Muriaticum 5CH at the rate of 3 granules per day, still being continued.
  • this example illustrates the fact that Hyperthyroidism is indeed a disease by intracellular NaCl deficiency, and that the prescription of NaCl 5CH by acting on the restoration of normal functioning of the transport systems, normalizes in an almost immediate manner thyroid hormone metabolisms that were disrupted.
  • Another disturbed metabolism returns to normal: it is the production of abnormal IgE type antibodies responsible for allergic rhinitis which completely ceases after a few months of treatment, and which had started to decrease and improve from the first doses homeopathic remedy.
  • Naprosyne Antimonium crudum 5CH 3 to 5 granules 1 time per day, this from 27-12.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/FR1992/000813 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques WO1994004186A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9110899A FR2680687A1 (fr) 1991-08-29 1991-08-29 Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales.
CA002142863A CA2142863A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques
AU25105/92A AU2510592A (en) 1991-08-29 1992-08-21 Homeopathic compositions for the treatment of viral and metabolic diseases
DE69223811T DE69223811T2 (de) 1991-08-29 1992-08-21 Verwendung eines homöopathisches Erzeugnisses zur Herstellung eines Arzneimittels für die Behandlung von metabolischen Krankheiten
EP92918959A EP0655928B1 (fr) 1991-08-29 1992-08-21 Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques
PCT/FR1992/000813 WO1994004186A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9110899A FR2680687A1 (fr) 1991-08-29 1991-08-29 Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales.
CA002142863A CA2142863A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques
PCT/FR1992/000813 WO1994004186A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08381884 A-371-Of-International 1995-05-09
US23969899A Continuation 1995-05-09 1999-01-29

Publications (1)

Publication Number Publication Date
WO1994004186A1 true WO1994004186A1 (fr) 1994-03-03

Family

ID=27169961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1992/000813 WO1994004186A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Country Status (3)

Country Link
CA (1) CA2142863A1 (enrdf_load_stackoverflow)
FR (1) FR2680687A1 (enrdf_load_stackoverflow)
WO (1) WO1994004186A1 (enrdf_load_stackoverflow)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7374892B2 (en) 1997-06-13 2008-05-20 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
WO2011143609A1 (en) * 2010-05-14 2011-11-17 Deseret Biologicals, Inc. Formulations of diluted genetic material and methods for making same
US9603898B2 (en) 2011-03-23 2017-03-28 Deseret Biologicals, Inc. Formulations of diluted amino acid segments and methods for making same

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713487B1 (fr) * 1993-12-09 1996-02-02 Labo Life Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène.
GB9426409D0 (en) * 1994-12-30 1995-03-01 Britannia Health Products Ltd A composition for treating endometriosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315552A1 (fr) * 1987-10-08 1989-05-10 Medibrevex Sa Nouvelles formes galéniques d'oeufs de caille pour administration par voie per- et sublinguale dans le traitement des maladies allergiques et leur procédé de préparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315552A1 (fr) * 1987-10-08 1989-05-10 Medibrevex Sa Nouvelles formes galéniques d'oeufs de caille pour administration par voie per- et sublinguale dans le traitement des maladies allergiques et leur procédé de préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.NETIEN ET AL 'galenica 16 médicaments homéopathiques' 1986 , TECHNIQUE ET DOCUMENTATION , PARIS, FR *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595385B2 (en) 1996-04-04 2009-09-29 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7998680B2 (en) 1996-04-04 2011-08-16 Bio-Rad Laboratories, Inc. Determining genotype of a polymorphic site in the hereditary hemochromatosis gene
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7052845B2 (en) 1996-04-04 2006-05-30 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7067255B2 (en) 1996-04-04 2006-06-27 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene
US7078513B1 (en) 1996-04-04 2006-07-18 Bio-Rad Laboratories, Inc. Plasmids comprising nucleic acids from the hereditary hemochromatosis gene
US8257927B2 (en) 1996-04-04 2012-09-04 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene
US7579169B2 (en) 1996-04-04 2009-08-25 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7374765B2 (en) 1996-05-23 2008-05-20 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US7374892B2 (en) 1997-06-13 2008-05-20 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
WO2011143609A1 (en) * 2010-05-14 2011-11-17 Deseret Biologicals, Inc. Formulations of diluted genetic material and methods for making same
US9603898B2 (en) 2011-03-23 2017-03-28 Deseret Biologicals, Inc. Formulations of diluted amino acid segments and methods for making same
US10213486B2 (en) 2011-03-23 2019-02-26 Deseret Biologicals, Inc. Formulations of diluted amino acid segments and methods for making same

Also Published As

Publication number Publication date
CA2142863A1 (fr) 1994-03-03
FR2680687A1 (fr) 1993-03-05
FR2680687B1 (enrdf_load_stackoverflow) 1995-03-24

Similar Documents

Publication Publication Date Title
Cicone et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate
Prantera et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
Terris et al. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis
Amlal et al. Early polyuria and urinary concentrating defect in potassium deprivation
Whelton et al. Doxycycline pharmacokinetics in the absence of renal function
Wilson et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease
JP2005538093A5 (enrdf_load_stackoverflow)
EP0388434A1 (en) Differential delivery of therapeutic agents across the blood brain barrier
Vyth et al. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants
Green et al. comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months
WO1994004186A1 (fr) Compositions homeopathiques pour le traitement des maladies virales et metaboliques
Snyder et al. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial
Van Ree et al. Antipsychotic effect of γ-type endorphins in schizophrenia
Gwaltney-Brant et al. Newer antidotal therapies
Stark et al. Dissolution of Cystine Calculi by Pelviocaliceal Irrigation with B-Penicillamine
EP0655928B1 (fr) Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques
US20170119707A1 (en) Homeopathic topical gel for transdermal delivery of colchicine formulations and method of use
Menne et al. Treatment of nickel dermatitis.(The influence of tetraethylthiuramdisulfide (Antabuse) on nickel metabolism)
Peterson et al. Cholecalciferol rodenticide intoxication in a cat
Oettmeier et al. The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects
Nogue et al. Acute thallium poisoning: an evaluation of different forms of treatment
NELDNER et al. Scleroderma: an evaluation of treatment with disodium edetate
Sutherland et al. Effect of the size of an oral dose of aluminium on the relative importance of biliary v. urinary aluminium excretion in conscious rats
Miller et al. Zomepirac-induced renal failure
Volkman et al. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1992918959

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2142863

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 381884

Country of ref document: US

Date of ref document: 19950509

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1992918959

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992918959

Country of ref document: EP